Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Abstract B006: Targeting BARD1 in human pancreatic ductal adenocarcinoma: How to expand the target population of vulnerable tumors?

Aditi Jain, Rutuj P. Kusurkar, Eleanor Jenkins, Avinoam Nevler, Wei Jiang, Charles J. Yeo

Cancer Res (2024) 84 (1_Supplement): B006.

https://doi.org/10.1158/1538-7445.DNAREPAIR24-B006

Published: 09 January 2024

View article titled, Abstract B006: Targeting BARD1 in human pancreatic ductal adenocarcinoma: How to expand the target population of vulnerable tumors?

Journal Articles

Abstract 6102: Targeting BARD1 slows PDAC growth in vitro and in vivo and sensitizes cells to DNA damaging agents

Sohum Patel, Anoohya Arkala, Avinoam Nevler, Carolyn Coats, Charles J. Yeo, Aditi Jain

Cancer Res (2023) 83 (7_Supplement): 6102.

https://doi.org/10.1158/1538-7445.AM2023-6102

Published: 04 April 2023

View article titled, Abstract 6102: Targeting BARD1 slows PDAC growth in vitro and in vivo and sensitizes cells to DNA damaging agents

Journal Articles

Abstract 2597: Inhibition of BARD1-PLK1 axis enhances PARP inhibitor/platinum sensitivity in homologous repair proficient pancreatic ductal adenocarcinoma

Carolyn Coats, Anoohya Arkala, Eric Londin, Avinoam Nevler, Jonathan R. Brody, Charles J. Yeo, Aditi Jain

Cancer Res (2022) 82 (12_Supplement): 2597.

https://doi.org/10.1158/1538-7445.AM2022-2597

Published: 15 June 2022

View article titled, Abstract 2597: Inhibition of BARD1-PLK1 axis enhances PARP inhibitor/platinum sensitivity in homologous repair proficient pancreatic ductal adenocarcinoma

Journal Articles

Abstract 1811: Dithiazanine Iodide suppresses mitochondrial function to strongly inhibit pancreatic ductal adenocarcinoma growth in-vitro and in-vivo, producing a marked increase in survival

Avinoam Nevler, Christopher W. Schultz, Aditi Jain, Saed Khalilieh, Grace McCarthy, Harish Lavu, Wilbur Bowne, Charles J. Yeo, Jonathan R. Brody

Cancer Res (2022) 82 (12_Supplement): 1811.

https://doi.org/10.1158/1538-7445.AM2022-1811

Published: 15 June 2022

View article titled, Abstract 1811: Dithiazanine Iodide suppresses mitochondrial function to strongly inhibit pancreatic ductal adenocarcinoma growth in-vitro and in-vivo, producing a marked increase in survival

Journal Articles

Abstract LB-203: The mRNA binding protein Human Antigen R (HuR, ELAVL1) is a novel regulator in pancreatic ductal adenocarcinoma metastatic progression and persistence

Grace A. McCarthy, Aditi Jain, Samantha Z. Brown, Charles J. Yeo, Jonathan Brody

Cancer Res (2020) 80 (16_Supplement): LB-203.

https://doi.org/10.1158/1538-7445.AM2020-LB-203

Published: 15 August 2020

View article titled, Abstract LB-203: The mRNA binding protein Human Antigen R (HuR, ELAVL1) is a novel regulator in pancreatic ductal adenocarcinoma metastatic progression and persistence

Journal Articles

Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer

Cancer Res (2019) 79 (17): 4491–4502.

https://doi.org/10.1158/0008-5472.CAN-18-3645

Published: 03 September 2019

View article titled, Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer

Includes: Supplementary data

Journal Articles

Abstract 3058: Recharacterizing the FDA approved drug pyrvinium pamoate as a clinically relevant HuR inhibitor in pancreatic ductal adenocarcinoma

Christopher W. Schultz, Teena Dhir, Samantha Z. Brown, Saswati Chand, Wei Jiang, Grace A. McCarthy, Alex O. Haber, Charles J. Yeo, Austin Goetz, Avinoam Nevler, Oloruntoba Bolaji, Jonathan R. Brody

Cancer Res (2019) 79 (13_Supplement): 3058.

https://doi.org/10.1158/1538-7445.AM2019-3058

Published: 01 July 2019

View article titled, Abstract 3058: Recharacterizing the FDA approved drug pyrvinium pamoate as a clinically relevant HuR inhibitor in pancreatic ductal adenocarcinoma

Journal Articles

Abstract 4764: A global transcriptome analysis of pancreatic cancer cells distinguishes between acute and acquired PARP inhibitor resistance mechanisms

Aditi Jain, Matthew McCoy, Lebaron A. Agostini, Yuriy Gusev, Subha Madhavan, Michael Pishvaian, Sankar Addya, Eric Londin, Maria R. Gurevich, Chani Stossel, Talia Golan, Charles J. Yeo, Jonathan R. Brody

Cancer Res (2019) 79 (13_Supplement): 4764.

https://doi.org/10.1158/1538-7445.AM2019-4764

Published: 01 July 2019

View article titled, Abstract 4764: A global transcriptome analysis of pancreatic cancer cells distinguishes between acute and acquired PARP inhibitor resistance mechanisms

Journal Articles

Abstract 1973: Targeting PARG in pancreatic cancer: Implications for synthetic lethal therapeutic strategies

Saswati N. Chand, AnnJosette Ramirez, Aditi Jain, Avinoam Nevler, Cinthya Yabar-Lowder, Joseph A. Cozzitorto, Dominic I. James, Allan Jordan, Kate M. Smith, Ian Waddell, Charles J. Yeo, Jordan M. Winter, Jonathan R. Brody

Cancer Res (2018) 78 (13_Supplement): 1973.

https://doi.org/10.1158/1538-7445.AM2018-1973

Published: 01 July 2018

View article titled, Abstract 1973: Targeting PARG in pancreatic cancer: Implications for synthetic lethal therapeutic strategies

Journal Articles

Abstract 1961: Gaps in the armor: Targeting HuR to sensitize pancreatic cancer

Cancer Res (2018) 78 (13_Supplement): 1961.

https://doi.org/10.1158/1538-7445.AM2018-1961

Published: 01 July 2018

View article titled, Abstract 1961: Gaps in the armor: Targeting HuR to sensitize pancreatic cancer

Journal Articles

Abstract 4441: Functional and clinical implications of an INDEL within the HuR regulatory region of the mitotic kinase inhibitor WEE1

Samantha Z. Brown, Avinoam Nevler, Henry T. Thomsett, Shruti Lal, Mahsa Zarei, Fernando Blanco, Joseph A. Cozzitorto, Alexis L. Norris-Kirby, Charles J. Yeo, Jordan M. Winter, James R. Eshleman, Jonathan R. Brody

Cancer Res (2018) 78 (13_Supplement): 4441.

https://doi.org/10.1158/1538-7445.AM2018-4441

Published: 01 July 2018

View article titled, Abstract 4441: Functional and clinical implications of an INDEL within the HuR regulatory region of the mitotic kinase inhibitor WEE1

Journal Articles

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors

Saswati N. Chand, Mahsa Zarei, Matthew J. Schiewer, Akshay R. Kamath, Carmella Romeo, Shruti Lal, Joseph A. Cozzitorto, Avinoam Nevler, Laura Scolaro, Eric Londin, Wei Jiang, Nicole Meisner-Kober, Michael J. Pishvaian, Karen E. Knudsen, Charles J. Yeo, John M. Pascal, Jordan M. Winter, Jonathan R. Brody

Cancer Res (2017) 77 (18): 5011–5025.

https://doi.org/10.1158/0008-5472.CAN-16-2704

Published: 14 September 2017

View article titled, Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors

Includes: Supplementary data

Journal Articles

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells

Mahsa Zarei, Shruti Lal, Seth J. Parker, Avinoam Nevler, Ali Vaziri-Gohar, Katerina Dukleska, Nicole C. Mambelli-Lisboa, Cynthia Moffat, Fernando F. Blanco, Saswati N. Chand, Masaya Jimbo, Joseph A. Cozzitorto, Wei Jiang, Charles J. Yeo, Eric R. Londin, Erin L. Seifert, Christian M. Metallo, Jonathan R. Brody, Jordan M. Winter

Cancer Res (2017) 77 (16): 4460–4471.

https://doi.org/10.1158/0008-5472.CAN-17-0015

Published: 14 August 2017

View article titled, Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells

Includes: Supplementary data

Journal Articles

Abstract 812: Multiplatform modeling of pancreatic cancer using patient-derived cells: A new approach for defining drug resistance mechanisms

Erika Maria Parasido, Praathibha Sripadhan, George Avetian, Richard Schlegel, Jonathan Brody, Jordan Winter, Charles J. Yeo, Michael J. Pishvaian, Erik Glasgow, Stephen Byers, Christopher Albanese

Cancer Res (2017) 77 (13_Supplement): 812.

https://doi.org/10.1158/1538-7445.AM2017-812

Published: 01 July 2017

View article titled, Abstract 812: Multiplatform modeling of pancreatic cancer using patient-derived cells: A new approach for defining drug resistance mechanisms

Journal Articles

Abstract 2854: CRISPR knockout of HuR in pancreatic cancer cells causes a xenograft lethal phenotype

Edwin Cheung, Shruti Lal, Mahsa Zarei, Nicole C. Mambelli-Lisboa, Saswati Chand, Carmella Romeo, Kevin O’Hayer, Eric Londin, Joseph A. Cozzitorto, Charles J. Yeo, Jordan M. Winter, Jonathan R. Brody

Cancer Res (2016) 76 (14_Supplement): 2854.

https://doi.org/10.1158/1538-7445.AM2016-2854

Published: 15 July 2016

View article titled, Abstract 2854: CRISPR knockout of HuR in pancreatic cancer cells causes a xenograft lethal phenotype

Journal Articles

Abstract 1847: The mRNA-binding protein HuR, regulates mutant and wild type IDH1 expression in IDH1-mutated cancer

Mahsa Zarei, Shruti Lal, Nicole C. Mambelli-Lisboa, Edwin Cheung, Saswati N. Chand, Charles J. Yeo, Jonathan R. Brody, Jordan M. Winter

Cancer Res (2016) 76 (14_Supplement): 1847.

https://doi.org/10.1158/1538-7445.AM2016-1847

Published: 15 July 2016

View article titled, Abstract 1847: The mRNA-binding protein HuR, regulates mutant and wild type IDH1 expression in IDH1-mutated cancer

Journal Articles

Abstract 1995: HuR dependent inhibition of PARG enhances PARP inhibitor therapy for DNA repair proficient and deficient pancreatic cancer cells

Saswati N. Chand, Mahsa Zarei, Akshay R. Kamath, Matthew J. Schiewer, Carmella Romeo, Joseph A. Cozzitorto, Nicole Meisner-Kober, Eric Londin, Isidore Rigoutsos, Karen Knudsen, John M. Pascal, Charles J. Yeo, Jordan M. Winter, Jonathan R. Brody

Cancer Res (2016) 76 (14_Supplement): 1995.

https://doi.org/10.1158/1538-7445.AM2016-1995

Published: 15 July 2016

View article titled, Abstract 1995: HuR dependent inhibition of PARG enhances PARP inhibitor therapy for DNA repair proficient and deficient pancreatic cancer cells

Journal Articles

Abstract 5476: A novel PARP inhibitor resistance mechanism mediated by the RNA-binding protein HuR

Saswati N. Chand, Akshay R. Kamath, Nicole Meisner-Kober, Charles J. Yeo, Jordan M. Winter, Jonathan R. Brody

Cancer Res (2015) 75 (15_Supplement): 5476.

https://doi.org/10.1158/1538-7445.AM2015-5476

Published: 01 August 2015

View article titled, Abstract 5476: A novel PARP inhibitor resistance mechanism mediated by the RNA-binding protein HuR

Journal Articles

Abstract 5133: The RNA-binding protein HuR facilitates proliferation and metastasis in human pancreatic ductal adenocarcinoma

Masaya Jimbo, Fernando F. Blanco, Brad Screnci, Gabriela Cosma, Vitali Alexeev, Yu-Hung Huang, Jordan M. Winter, Charles J. Yeo, Janet A. Sawicki, Jonathan R. Brody

Cancer Res (2015) 75 (15_Supplement): 5133.

https://doi.org/10.1158/1538-7445.AM2015-5133

Published: 01 August 2015

View article titled, Abstract 5133: The RNA-binding protein HuR facilitates proliferation and metastasis in human pancreatic ductal adenocarcinoma

Journal Articles

Abstract 1656: MK-1775 (WEE1 inhibition) lacks efficacy against DNA repair deficient pancreatic cancer cells

Shruti Lal, Saswati N. Chand, Emanuela Dylgjeri, Charles J. Yeo, Jordan M. Winter, Jonathan R. Brody

Cancer Res (2015) 75 (15_Supplement): 1656.

https://doi.org/10.1158/1538-7445.AM2015-1656

Published: 01 August 2015

View article titled, Abstract 1656: MK-1775 (WEE1 inhibition) lacks efficacy against DNA repair deficient pancreatic cancer cells

NARROW

Abstract B006: Targeting BARD1 in human pancreatic ductal adenocarcinoma: How to expand the target population of vulnerable tumors?

Abstract 6102: Targeting BARD1 slows PDAC growth in vitro and in vivo and sensitizes cells to DNA damaging agents

Abstract 2597: Inhibition of BARD1-PLK1 axis enhances PARP inhibitor/platinum sensitivity in homologous repair proficient pancreatic ductal adenocarcinoma

Abstract 1811: Dithiazanine Iodide suppresses mitochondrial function to strongly inhibit pancreatic ductal adenocarcinoma growth in-vitro and in-vivo, producing a marked increase in survival

Abstract LB-203: The mRNA binding protein Human Antigen R (HuR, ELAVL1) is a novel regulator in pancreatic ductal adenocarcinoma metastatic progression and persistence

Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer

Abstract 3058: Recharacterizing the FDA approved drug pyrvinium pamoate as a clinically relevant HuR inhibitor in pancreatic ductal adenocarcinoma

Abstract 4764: A global transcriptome analysis of pancreatic cancer cells distinguishes between acute and acquired PARP inhibitor resistance mechanisms

Abstract 1973: Targeting PARG in pancreatic cancer: Implications for synthetic lethal therapeutic strategies

Abstract 1961: Gaps in the armor: Targeting HuR to sensitize pancreatic cancer

Abstract 4441: Functional and clinical implications of an INDEL within the HuR regulatory region of the mitotic kinase inhibitor WEE1

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells

Abstract 812: Multiplatform modeling of pancreatic cancer using patient-derived cells: A new approach for defining drug resistance mechanisms

Abstract 2854: CRISPR knockout of HuR in pancreatic cancer cells causes a xenograft lethal phenotype

Abstract 1847: The mRNA-binding protein HuR, regulates mutant and wild type IDH1 expression in IDH1-mutated cancer

Abstract 1995: HuR dependent inhibition of PARG enhances PARP inhibitor therapy for DNA repair proficient and deficient pancreatic cancer cells

Abstract 5476: A novel PARP inhibitor resistance mechanism mediated by the RNA-binding protein HuR

Abstract 5133: The RNA-binding protein HuR facilitates proliferation and metastasis in human pancreatic ductal adenocarcinoma

Abstract 1656: MK-1775 (WEE1 inhibition) lacks efficacy against DNA repair deficient pancreatic cancer cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only